Monitor for any further increases or conversion to a 13D filing, which would signal activist intent. The passive nature of this filing suggests no near-term catalyst from Morgan Stanley.
Price Chart
Executive Summary
Morgan Stanley filed an amended Schedule 13G disclosing a 12.2% passive stake in Arbutus Biopharma Corp as of September 30, 2026, up from the prior filing's undisclosed level. The filing confirms Morgan Stanley's continued passive investment without intent to influence control.
Key Financial Metrics
Key Facts
- Morgan Stanley reported beneficial ownership of 18,682,708 common shares (12.2% of shares outstanding) as of September 30, 2026.
- Morgan Stanley Investment Management Inc. holds 17,376,366 shares (11.3%) as an investment adviser.
- The filing is a passive Schedule 13G/A under Rule 13d-1(b), indicating no intent to change or influence control.
- The stake increased from the prior filing (August 12, 2026) which did not disclose a percentage, but the current 12.2% is a material passive position.
Financial Impact
Morgan Stanley holds 18.68 million shares, representing 12.2% of Arbutus Biopharma. No transaction values disclosed.
Risk Factors
- Potential for Morgan Stanley to reduce stake, which could pressure the stock.
- No indication of activist intent, limiting upside catalyst from this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000895421-26-000284 |
| Exhibit: EXHIBIT_NO.99.2.txt | 0000895421-26-000284 |
| Document: 0000895421-26-000284-index-headers.html | 0000895421-26-000284 |
| Document: 0000895421-26-000284-index.html | 0000895421-26-000284 |
| Document: 0000895421-26-000284.txt | 0000895421-26-000284 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $4.21 | awaiting T+60 | — | $4.29 (+1.90%) |
Oct 22, 2026 5d ago | Press Release | $4.21 | awaiting T+60 | — | $4.29 (+1.90%) |
Oct 7, 2026 20d ago | SC 13G/A | $4.18 | awaiting T+60 | — | $4.29 (+2.63%) |
Oct 5, 2026 22d ago | SC 13D/A | $4.48 | awaiting T+60 | — | $4.29 (−4.24%) |
Oct 1, 2026 26d ago | SC TO-I/A | $4.56 | awaiting T+60 | — | $4.29 (−5.92%) |
Oct 1, 2026 26d ago | Press Release | $4.56 | awaiting T+60 | — | $4.29 (−5.92%) |
Sep 30, 2026 27d ago | SC TO-I/A | $4.78 | awaiting T+60 | — | $4.29 (−10.25%) |
Sep 30, 2026 27d ago | Press Release | $4.78 | awaiting T+60 | — | $4.29 (−10.25%) |
Aug 21, 2026 9w ago | 8-K | $5.21 | awaiting T+60 | — | $4.29 (−17.66%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.71 | awaiting T+60 | — | $4.29 (−8.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers